Trastornos del estado de ánimo y psicóticos

1. Amare, A.T. , Schubert, K.O. , Klingler-Hoffmann, M. , Cohen–Woods, S. , Baune, B.T. , 2017. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic re- view of genome wide and candidate gene studies. Trans. Psychi- atry 7, e1007 .

2. Baldassano, S. , Amato, A. , Mule, F. , 2016. Influence of glucagon-like peptide 2 on energy homeostasis. Peptides 86, 1–5 .

3.Bertilsson, G. , Patrone, C. , Zachrisson, O. , Andersson, A. , Dan- naeus, K. , Heidrich, J. , Kortesmaa, J. , Mercer, A. , Nielsen, E. , Ronnholm, H. , Wikstrom, L. , 2008. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J. Neurosci. Res. 86, 326–338 .

4.Brietzke, E. , Kapczinski, F. , Grassi-Oliveira, R. , Grande, I. , Vi- eta, E. , McIntyre, R.S., 2011. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev. Neurother. 11, 1017–1028.

5.Calkin, C.V. , Gardner, D.M. , Ransom, T. , Alda, M. , 2013. The relationship between bipolar disorder and Type 2 diabetes: more than just co-morbid disorders. Ann. Med. 45, 171–181

6. Carter, J. , Swardfager, W. , 2016. Mood and metabolism: anhedonia as a clinical target in type 2 diabetes. Psychoneuroendocrinol- ogy 69, 123–132 .

7.Cheadle, C. , Vawter, M.P. , Freed, W.J. , Becker, K.G. , 2003. Analysis of microarray data using Z score transformation. J. Mol. Diagn. 5, 73–81

8. During, M.J. , Cao, L. , Zuzga, D.S. , Francis, J.S. , Fitzsimons, H.L. , Jiao, X. , Bland, R.J. , Klugmann, M. , Banks, W.A. , Drucker, D.J. , Haile, C.N. , 2003. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173–1179 . 9.Farr, O.M. , Sofopoulos, M. , Tsoukas, M.A. , Dincer, F. , Thakkar, B. , Sahin-Efe, A. , Filippaios, A. , Bowers, J. , Srnka, A. , Gavrieli, A. , Ko, B.J. , Liakou, C. , Kanyuch, N. , Tseleni-Balafouta, S. , Mant- zoros, C.S. , 2016. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 59, 954–965 .

10. Gault, V.A., Hölscher, C., 2008. GLP-1 agonists facilitate hippocam- pal LTP and reverse the impairment of LTP induced by beta- amyloid. Eur. J. Pharmacol. 587 (1–3), 112–117. doi: 10.1016/j. ejphar.2008.03.025.

11. Gault, V.A. , Porter, W.D. , Flatt, P.R. , Holscher, C. , 2010. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes. (Lond.) 34, 1341–1344 .

12. Gengler, S. , McClean, P.L. , McCurtin, R. , Gault, V.A. , Holscher, C. , 2012. Val (8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33, 265–276.

13. Gumuslu, E. Cine, N. Ertan, M. Mutlu, O. Komsuoglu Celikyurt, I. , Ulak, G. , 2018. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice. Fundam. Clin. Pharmacol. 32, 174–180 .

14.Henderson, D.C. , Vincenzi, B. , Andrea, N.V. , Ulloa, M. , Copeland, P.M. , 2015. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2, 452– 464 .

15 Heni, M. , Kullmann, S. , Gallwitz, B. , Haring, H.U. , Preissl, H. , Fritsche, A. , 2015. Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans. Mol. Metab. 4, 971– 976 .

16.Ishoy, P.L. , Fagerlund, B. , Broberg, B.V. , Bak, N. , Knop, F.K. , Glen- thoj, B.Y. , Ebdrup, B.H. , 2017. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr. Scand. .

17 Iwai, T. , Ito, S. , Tanimitsu, K. , Udagawa, S. , Oka, J. , 2006. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta produc- tion in cultured rat astrocytes. Neurosci. Res. 55, 352–360 .

18.Iwai, T. , Suzuki, M. , Kobayashi, K. , Mori, K. , Mogi, Y. , Oka, J. , 2009. The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neurosci. Res. 64, 67–74 .

18. Kappe, C. , Tracy, L.M. , Patrone, C. , Iverfeldt, K. , Sjoholm, A. , 2012. GLP-1 secretion by microglial cells and decreased CNS ex pression in obesity. J. Neuroinflammation 9, 276 .

19.Kobayashi, K., Iwai, T., Sasaki-Hamada, S., Kamanaka, G., Oka, J., 2013. Exendin (5–39), an antagonist of GLP-1 receptor, modulates synaptic transmission via glutamate uptake in the dentate gyrus. Brain Res. 1505, 1–10. doi: 10.1016/j.brainres.2013. 01.012 . 20. Lee, Y.S. , Park, M.S. , Choung, J.S. , Kim, S.S. , Oh, H.H. , Choi, C.S. , Ha, S.Y. , Kang, Y. , Kim, Y. , Jun, H.S. , 2012. Glucagon-like pep- tide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55, 2456– 2468.

21 Li, Y. , Duffy, K.B. , Ottinger, M.A. , Ray, B. , Bailey, J.A. , Holloway, H.W. , Tweedie, D. Perry, T. , Mattson, M.P. , Kapogiannis, D. , Sambamurti, K. , Lahiri, D.K. , Greig, N.H. , 2010. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J. Alzheimers Dis. 19, 1205–1219.

22. Lipska, B.K. , Deep-Soboslay, A. , Weickert, C.S. , Hyde, T.M. , Mar- tin, C.E. , Herman, M.M. , Kleinman, J.E. , 2006. Critical factors in gene expression in postmortem human brain: focus on studies in schizophrenia. Biol. Psychiatry 60, 650–658.

23. Mansur, R.B. , Ahmed, J. , Cha, D.S. , Woldeyohannes, H.O., Subra- maniapillai, M. , Lovshin, J. , Lee, J.G. , Lee, J.H. , Brietzke, E. , Reininghaus, E.Z. , Sim, K. , Vinberg, M. , Rasgon, N. , Hajek, T. , McIntyre, R.S. , 2017a. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J. Affect Disord. 207, 114–120